Bifogade filer
BrainCool AB (publ) – the first patient has been treated with RhinoChill® System in the pivotal COTTIS 2 study
Kurs
+8,47%
Likviditet
1,05 MSEK
Prenumeration
Kalender
| Tid* | ||
| 2025-02-11 | 18:00 | Bokslutskommuniké 2024 |
| 2024-11-01 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-15 | - | Kvartalsrapport 2024-Q2 |
| 2024-06-26 | - | Årsstämma |
| 2024-04-26 | - | X-dag ordinarie utdelning BRAIN 0.00 SEK |
| 2024-04-15 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-29 | - | Bokslutskommuniké 2023 |
| 2023-11-30 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-31 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-31 | - | Kvartalsrapport 2023-Q1 |
| 2023-05-12 | - | X-dag ordinarie utdelning BRAIN 0.00 SEK |
| 2023-05-11 | - | Årsstämma |
| 2023-02-28 | - | Bokslutskommuniké 2022 |
| 2023-02-15 | - | Extra Bolagsstämma 2022 |
| 2022-11-30 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-31 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-31 | - | Kvartalsrapport 2022-Q1 |
| 2022-05-12 | - | X-dag ordinarie utdelning BRAIN 0.00 SEK |
| 2022-05-11 | - | Årsstämma |
| 2022-02-28 | - | Bokslutskommuniké 2021 |
| 2021-11-30 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-26 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-31 | - | Kvartalsrapport 2021-Q1 |
| 2021-04-16 | - | X-dag ordinarie utdelning BRAIN 0.00 SEK |
| 2021-04-15 | - | Årsstämma |
| 2021-02-26 | - | Bokslutskommuniké 2020 |
| 2020-11-27 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-28 | - | Kvartalsrapport 2020-Q2 |
| 2020-07-01 | - | X-dag ordinarie utdelning BRAIN 0.00 SEK |
| 2020-06-30 | - | Årsstämma |
| 2020-05-29 | - | Kvartalsrapport 2020-Q1 |
| 2020-04-29 | - | X-dag ordinarie utdelning BRAIN 0.00 SEK |
| 2020-02-28 | - | Bokslutskommuniké 2019 |
| 2019-11-08 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-30 | - | Kvartalsrapport 2019-Q2 |
| 2019-06-17 | - | Årsstämma |
| 2019-04-08 | - | X-dag ordinarie utdelning BRAIN 0.00 SEK |
| 2019-02-28 | - | Bokslutskommuniké 2018 |
| 2018-11-16 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-27 | - | Kvartalsrapport 2018-Q2 |
| 2018-07-25 | - | Extra Bolagsstämma 2018 |
| 2018-05-09 | - | Kvartalsrapport 2018-Q1 |
| 2018-04-19 | - | X-dag ordinarie utdelning BRAIN 0.00 SEK |
| 2018-04-18 | - | Årsstämma |
| 2018-02-16 | - | Bokslutskommuniké 2017 |
| 2017-11-23 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-10 | - | Kvartalsrapport 2017-Q2 |
| 2017-06-29 | - | Årsstämma |
| 2017-05-15 | - | Kvartalsrapport 2017-Q1 |
| 2017-04-24 | - | Extra Bolagsstämma 2017 |
| 2017-04-12 | - | X-dag ordinarie utdelning BRAIN 0.00 SEK |
| 2017-02-14 | - | Bokslutskommuniké 2016 |
| 2016-11-10 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-25 | - | Kvartalsrapport 2016-Q2 |
| 2016-05-10 | - | Kvartalsrapport 2016-Q1 |
| 2016-04-14 | - | Årsstämma |
| 2016-03-27 | - | X-dag ordinarie utdelning BRAIN 0.00 SEK |
| 2016-01-28 | - | Bokslutskommuniké 2015 |
| 2015-10-22 | - | Kvartalsrapport 2015-Q3 |
| 2015-08-26 | - | Kvartalsrapport 2015-Q2 |
| 2015-04-28 | - | Kvartalsrapport 2015-Q1 |
| 2015-03-27 | - | X-dag ordinarie utdelning BRAIN 0.00 SEK |
| 2015-03-26 | - | Årsstämma |
| 2015-01-27 | - | Bokslutskommuniké 2014 |
| 2014-10-20 | - | Kvartalsrapport 2014-Q3 |
| 2014-08-19 | - | Kvartalsrapport 2014-Q2 |
| 2014-06-26 | - | X-dag ordinarie utdelning BRAIN 0.00 SEK |
| 2014-06-25 | - | Årsstämma |
| 2014-04-14 | - | Extra Bolagsstämma 2014 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
BrainCool AB (publ) can announce that the first patient has been treated with RhinoChill® System and BrainCool™ System during a thrombectomy procedure in the COTTIS 2 study.
The COTTIS 2 (Combination of Targeted temperature management and Thrombectomy after acute Ischemic Stroke) clinical trial intends to measure the outcome in acute stroke patients with large vessel occlusion treated with the combination of hypothermia and thrombectomy.
On June 28th, 2024, BrainCool AB communicated in a press release that all the criteria had been fulfilled to enroll the first patient in the pivotal COTTIS 2 trial, which is equivalent to a phase 3 clinical trial. COTTIS 2 is a multicenter randomized clinical trial with a total of 400 patients. Professor Dr. Jürgen Bardutzky at the University Hospital of Freiburg is the principal investigator of COTTIS 2.
Please see the press release mentioned above for more details regarding COTTIS 2 and ischemic stroke.
https://www.braincool.se/press-releases
Contact
For more information
Jon Berg - CEO
+46 722 50 91 19
E-mail: jon.berg@braincool.se
About Us
BrainCool AB (publ) is an innovative medical device company that develops, markets, and sells leading medical cooling systems for indications and areas with significant medical benefits within the healthcare sector. BrainCool AB (publ) is based in Lund, Sweden, and its share is listed on Nasdaq First North Growth Market, named “BRAIN”.
Eminova Fondkommission AB is the company’s Certified Adviser.